title: Apparent pokeweed mitogen cure of metastatic gum melanoma in an older dog.
abstract: Immunotherapy with plant mitogens has been of increasing interest to both authors, although their mutual attraction to these substances over the past two decades occurred independently and has taken divergent pathways from the start. Because of their clinical unavailability, Wimer's efforts have been confined to writing theoretical concepts on potential applications of the mitogens focusing on the L4 isolectin of PHA. Alternatively, Mann has worked actively with laboratory and experimental research involving PWM that he has extracted himself. As a sequel to a pilot study of PWM cancer treatment in pets whereby he supplies the mitogen, protocol, and data sheets and veterinarians supervise the administration, Mann acquiesced to widespread requests for inclusion in an extended investigation. Unfortunately, this arrangement has left Mann with little control over data submission, and until recently, only verbal reports have been received. The recent documentation of a three-year remission and apparent cure of gum melanoma metastatic to regional and hilar lymph nodes and to the lungs in an aged dog following PWM therapy has prompted this case report. The incredible response has inspired more aggressive attempts to obtain information from other recipients of the mitogen. The small total dose of 300 micrograms inducing a remission does speak for the remarkable potency of PWM that may be 500 or more times that of PHA. However, the possibility that melanoma is a uniquely responsive tumor is suggested by a 1971 article indicating complete remission of metastatic melanoma in an 18-year-old lad to an unexpectedly low total dose of 50 mg PHA. Preliminary reports on other tumors treated with PWM indicate some impressive responses have occurred, although they also suggest that Mann's regimen may sometimes require adjustments in dosages and other variables previously reviewed in theoretical PHA-L4 models, to which this case report now contributes validity.
authors.affiliation: JBMW Immunotherapeutics, Albuquerque, NM 87123-4255, USA.
authors.forename: B M
authors.initials: BM
authors.lastname: Wimer
authors.forename: P L
authors.initials: PL
authors.lastname: Mann
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D005887:Gingival Neoplasms / Q000556:secondary / Q000628:therapy / Q000662:veterinary*; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy / Q000662:veterinary; D008207:Lymphatic Metastasis; D008545:Melanoma / Q000556:secondary / Q000628:therapy / Q000662:veterinary*; D011043:Pokeweed Mitogens / Q000627:therapeutic use*; D012074:Remission Induction
chemical_list: D000276:Adjuvants, Immunologic; D011043:Pokeweed Mitogens